Å®ÉúСÊÓƵ

With excavation set to begin later this spring for our stunning, new, state-of-the-art Global R&D Centre and Corporate Headquarters in Cambridge, this truly is a significant milestone for our company. It’s also a momentous event for the Campus which, dating back to the ‘60s, has played a major role in establishing Cambridge as a global centre of biopharmaceutical excellence. Having attracted world-leading academic scientists and clinicians, as well as producing new biotech start-ups, today the Campus is a thriving hub of innovation and collaboration. At AstraZeneca, we’re excited about contributing to this culture of success and helping the Campus realise its vision of becoming one of the leading biomedical centres in the world by 2020.

Open innovation for a greater impact

Ground-breaking science and collaborative innovation lies at the heart of our work and these new premises will foster an open, supportive environment of active, collaborative learning. Whether working in the labs or in Biometrics, in Projects or Regulatory, there are opportunities for everyone to learn about, and contribute to, the success of our research, drug development and commercial growth.

While we already collaborate with a myriad of external organisations, we’re excited to make even more of these connections in Cambridge. It’s our belief that by openly collaborating, we can accelerate the development of new medicines, and make a greater difference for patients, their families, our stakeholders, and society in general.

A cutting-edge portfolio

We constantly work at the forefront of biopharmaceutical research. To ensure we do this as successfully and efficiently as possible, we’ve focused our research on three therapeutic areas: cardiovascular and metabolic diseases, oncology, and respiratory, inflammation and autoimmunity.

Take our work in oncology for example. For over 40 years, we have developed cancer drugs which have contributed to significantly increased survival rates for cancer patients around the world.

We’re also one of only a handful of companies conducting small molecule, large molecule and immuno-oncology research, and soon we’ll be doing it all under one roof. In 2014, our oncology pipeline has shown huge progress. Six of our assets are progressing into late stage clinical trials and 24 new molecular entities are currently in development between Phase I and Phase III. All this demonstrates that we’re committed to pushing the boundaries of science to become leaders in the field of oncology.

What science can do

It’s an exciting time to be a part of AstraZeneca, and our move to the Cambridge Biomedical Campus speaks volumes of the City’s global importance as a location for biopharmaceutical research and development. We’re focused on advancing the discovery and development of ground-breaking medicines and look forward to fostering collaborations that will help us drive medical progress, even further. With the chance to work closely with world-renowned academic research institutions, pre-eminent hospitals and cutting-edge biotech companies, we can’t wait to see what science can do.

To find out more about AstraZeneca’s boundary-breaking science in Cambridge, visit